What is he best known for?
The fields of study he is best known for:
Peter Parham spends much of his time researching Human leukocyte antigen, Genetics, Immunology, Molecular biology and Major histocompatibility complex.
His Human leukocyte antigen study integrates concerns from other disciplines, such as Receptor and Natural killer cell.
His study in Gene, Allele, MHC class I, Killer-cell immunoglobulin-like receptor and Haplotype is done as part of Genetics.
The concepts of his MHC class I study are interwoven with issues in Acquired immune system and MHC class II.
His research in Immunology tackles topics such as Transplantation which are related to areas like Leukemia.
His Molecular biology research incorporates themes from T cell, Antigen, HLA-A, Cytotoxic T cell and Antibody.
His most cited work include:
- Nomenclature for factors of the HLA system, 2010. (1906 citations)
- The IPD and IMGT/HLA database: allele variant databases (1292 citations)
- MHC class I molecules and kirs in human history, health and survival (953 citations)
What are the main themes of his work throughout his whole career to date?
Peter Parham mostly deals with Genetics, Human leukocyte antigen, Immunology, Major histocompatibility complex and Molecular biology.
Gene, Allele, Haplotype, MHC class I and Locus are the primary areas of interest in his Genetics study.
His research in Human leukocyte antigen intersects with topics in Epitope, Antibody and Receptor.
His Epitope research is multidisciplinary, relying on both HLA-B Antigens and Peptide sequence.
His Immunology research is multidisciplinary, incorporating perspectives in Hematopoietic stem cell transplantation and Transplantation.
His Molecular biology study incorporates themes from Allotype, Complementary DNA, HLA-A, Cytotoxic T cell and Monoclonal antibody.
He most often published in these fields:
- Genetics (46.53%)
- Human leukocyte antigen (44.16%)
- Immunology (21.77%)
What were the highlights of his more recent work (between 2013-2021)?
- Human leukocyte antigen (44.16%)
- Genetics (46.53%)
- Haplotype (13.25%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Human leukocyte antigen, Genetics, Haplotype, Receptor and Allele.
His work carried out in the field of Human leukocyte antigen brings together such families of science as Epitope, Major histocompatibility complex and Transplantation.
His Haplotype study which covers Genotyping that intersects with DNA sequencing.
His research in Receptor focuses on subjects like Cell biology, which are connected to Clathrin and CD8.
His Allele research incorporates elements of Risk factor, Genetic diversity and Exon.
In his research, Molecular biology is intimately related to HLA-C, which falls under the overarching field of KIR2DL1.
Between 2013 and 2021, his most popular works were:
- The IPD and IMGT/HLA database: allele variant databases (1292 citations)
- Genomic evidence for the Pleistocene and recent population history of Native Americans (312 citations)
- Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia (107 citations)
In his most recent research, the most cited papers focused on:
Peter Parham focuses on Human leukocyte antigen, Genetics, Immunology, Receptor and Haplotype.
His Human leukocyte antigen study integrates concerns from other disciplines, such as Epitope, Immune system and KIR Ligand.
Peter Parham combines subjects such as Genotype and Transplantation with his study of Immunology.
His Receptor research is multidisciplinary, incorporating elements of Cell and Natural killer cell.
The Natural killer cell study combines topics in areas such as Evolutionary biology and Major histocompatibility complex.
His research integrates issues of Molecular biology and Balancing selection in his study of Allotype.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
